Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
GlaxoSmithKline vaccine delay and Novacyt's new virus strain test

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
GlaxoSmithKline (GSK) £14.00
Gain to date: 6%
Original entry point: Buy at £13.21, 5 November 2020
Novacyt (NCYT:AIM) 870.2p
Gain to date: 37.7%
Original entry point: Buy at 632p, 8 October 2020
Although delays to vaccines are common, given the positive slew of positive news over the last few weeks the three-month delay to the possible market launch of the GlaxoSmithKline (GSK) vaccine candidate (in partnership with Sanofi) was unfortunate.
The two companies now plan a new study starting in February with an improved formulation which will include a comparison with an authorized Covid-19 vaccine.
If the data from the trial is as hoped, a final trial will begin in the second quarter. Positive results from this trial would then lead to regulatory submissions in the second half of 2021, delaying the vaccine’s potential availability from mid-year to the final quarter.
Importantly there are no significant financial implications attached to the delay.
In a more positive Covid-linked corporate development Novacyt (NCYT:AIM) added to its diagnostic capabilities with the launch of a test (14 Dec) for the mutation of the Covid-19 virus associated with Danish Minks.
The mutation is of concern to scientists because it causes an amino acid change which affects antibody binding. The launch of the test puts Novacyt in a strong position should the need arise to differentiate the new strain.
SHARES SAYS: Despite somewhat divergent fortunes of late these are both still buys.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.